CD19 and myeloid sarcoma: Before the primary vaccination (T0), the proportion of CD19+ cells (C15) was significantly reduced in MS patients treated with BCD therapies (i.e., anti-CD20 monoclonal antibodies (aCD20); ocrelizumab and rituximab) or the S1P receptor antagonist fingolimod (FTY) (Fig. 1C and D), as were natural killer (NK) cells (C10 for interferon β (IFNβ) and C16 for aCD20 and FTY), FcεR1ahiCD11c+ DCs (C4), and CD14dimCD16dim (C14) and CD4+ T cells (C6).